StreetInsider.com News Articles

Form SCHEDULE 13G/A Neurogene Inc. Filed by: Redmile Group, LLC

Fri, 14 Aug 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260814/26931109.html

Form SCHEDULE 13G/A Neurogene Inc. Filed by: Redmile Group, LLC

Fri, 14 Aug 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260814/26931109.html

Form SCHEDULE 13G/A Neurogene Inc. Filed by: Trails Edge Capital Partners, LP

Fri, 14 Aug 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260814/26930968.html

Form SCHEDULE 13G/A Neurogene Inc. Filed by: Trails Edge Capital Partners, LP

Fri, 14 Aug 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260814/26930968.html

Form SCHEDULE 13G Neurogene Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.

Fri, 14 Aug 2026 06:09:00 -0400

si-local-file:///var/storage/secattach/20260814/26924126.html

Form SCHEDULE 13G Neurogene Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.

Fri, 14 Aug 2026 06:09:00 -0400

si-local-file:///var/storage/secattach/20260814/26924126.html

Neurogene (NGNE) PT Lowered to $65 at H.C. Wainwright

Wed, 12 Aug 2026 07:26:58 -0400

(Updated - August 12, 2026 7:26 AM EDT)

H.C. Wainwright analyst Mitchel Kapoor lowered the price target on Neurogene (NASDAQ: NGNE) to $65.00 (from $70.00) while maintaining a Buy rating.

The analyst commented: 'Neurogene initiated its Process Performance Qualification (PPQ) campaign last month and expects to complete runs by YE26, marking the next key execution step toward a potential Biologics License Application (BLA). The ~$144M gross proceeds from the recent follow-on offering generated ~$134.8M in net proceeds, taking pro forma cash to ~$360.2M and extending runway into 1Q29, comfortably beyond Embolden top-line data release in 2H27 and supporting planned commercial-readiness activities. Safety

Neurogene (NGNE) PT Lowered to $65 at H.C. Wainwright

Wed, 12 Aug 2026 07:26:58 -0400

(Updated - August 12, 2026 7:26 AM EDT)

H.C. Wainwright analyst Mitchel Kapoor lowered the price target on Neurogene (NASDAQ: NGNE) to $65.00 (from $70.00) while maintaining a Buy rating.

Neurogene (NGNE) PT Lowered to $166 at Canaccord

Wed, 12 Aug 2026 06:55:10 -0400

(Updated - August 12, 2026 6:55 AM EDT)

Canaccord analyst Whitney Ijem lowered the price target on Neurogene (NASDAQ: NGNE) to $166.00 (from $180.00) while maintaining a Buy rating.

The analyst commented: "NGNE's 2Q26 report was relatively uneventful following the longer follow-up data shared from its Phase 1/2 study of NGN-401 for Rett Syndrome and the presentation at the International Rett Syndrome Foundation meeting back in June (our thoughts here and here respectively). In July, the co initiated the PPQ campaign to support BLA filing; completion expected by YE26. Topline data from the Embolden registrational study continues to be expected 2H27. Maintain

Neurogene (NGNE) PT Lowered to $166 at Canaccord

Wed, 12 Aug 2026 06:55:10 -0400

(Updated - August 12, 2026 6:55 AM EDT)

Canaccord analyst Whitney Ijem lowered the price target on Neurogene (NASDAQ: NGNE) to $166.00 (from $180.00) while maintaining a Buy rating.

Form 10-Q Neurogene Inc. For: Jun 30

Tue, 11 Aug 2026 16:58:00 -0400

si-local-file:///var/storage/secattach/20260811/26906819.html

Form 10-Q Neurogene Inc. For: Jun 30

Tue, 11 Aug 2026 16:58:00 -0400

si-local-file:///var/storage/secattach/20260811/26906819.html

Neurogene (NGNE) Tops Q2 EPS by 38c

Tue, 11 Aug 2026 07:35:49 -0400

Neurogene (NASDAQ: NGNE) reported Q2 EPS of ($1.05), $0.38 better than the analyst estimate of ($1.43).

For earnings history and earnings-related data on Neurogene (NGNE) click here.

Form 8-K Neurogene Inc. For: Aug 11

Tue, 11 Aug 2026 07:33:00 -0400

si-local-file:///var/storage/secattach/20260811/26901469.html

Form 8-K Neurogene Inc. For: Aug 11

Tue, 11 Aug 2026 07:33:00 -0400

si-local-file:///var/storage/secattach/20260811/26901469.html

Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates

Tue, 11 Aug 2026 07:30:00 -0400

Data from Phase 1/2 trial of NGN-401 for Rett syndrome showed 100% of participants improved in CGI-I score and gained ≥1 developmental milestone, with an average of 4.7 milestones per participant; no plateau and no milestone loss observed as of data cutoff date of June 16, 2026

Milestones gained in a progressive, stepwise sequence, suggesting a restart of development post-treatment

Topline data from Embolden™ registrational trial anticipated in 2H 2027

NGN-401 at the 1E15 vg dose remains generally well-tolerated (N=35) as of data cutoff date of August 10, 2026

Initiated PPQ campaign to support BLA submission for NGN-401; completion

Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates

Tue, 11 Aug 2026 07:30:00 -0400

Data from Phase 1/2 trial of NGN-401 for Rett syndrome showed 100% of participants improved in CGI-I score and gained ≥1 developmental milestone, with an average of 4.7 milestones per participant; no plateau and no milestone loss observed as of data cutoff date of June 16, 2026
Milestones gained in a progressive, stepwise sequence, suggesting a restart of development post-treatment
Topline data from Embolden™ registrational trial anticipated in 2H 2027
NGN-401 at the 1E15 vg dose remains generally well-tolerated (N=35) as of data cutoff date of August 10, 2026
Initiated PPQ campaign to support BLA submission for NGN-401; completion

Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates

Tue, 11 Aug 2026 07:30:00 -0400

Data from Phase 1/2 trial of NGN-401 for Rett syndrome showed 100% of participants improved in CGI-I score and gained ≥1 developmental milestone, with an average of 4.7 milestones per participant; no plateau and no milestone loss observed as of data cutoff date of June 16, 2026
Milestones gained in a progressive, stepwise sequence, suggesting a restart of development post-treatment
Topline data from Embolden™ registrational trial anticipated in 2H 2027
NGN-401 at the 1E15 vg dose remains generally well-tolerated (N=35) as of data cutoff date of August 10, 2026
Initiated PPQ campaign to support BLA submission for NGN-401; completion

Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates

Tue, 11 Aug 2026 07:30:00 -0400

Data from Phase 1/2 trial of NGN-401 for Rett syndrome showed 100% of participants improved in CGI-I score and gained ≥1 developmental milestone, with an average of 4.7 milestones per participant; no plateau and no milestone loss observed as of data cutoff date of June 16, 2026
Milestones gained in a progressive, stepwise sequence, suggesting a restart of development post-treatment
Topline data from Embolden™ registrational trial anticipated in 2H 2027
NGN-401 at the 1E15 vg dose remains generally well-tolerated (N=35) as of data cutoff date of August 10, 2026
Initiated PPQ campaign to support BLA submission for NGN-401; completion

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 04 Aug 2026 16:01:00 -0400

NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 12,555 shares of the Company’s common stock to four new employees (the “Inducement Grants”) on August 3, 2026 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company’s 2025 Inducement Plan. The Inducement Grants were granted as an inducement material to these individuals entering into

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 04 Aug 2026 16:01:00 -0400

NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 12,555 shares of the Company’s common stock to four new employees (the “Inducement Grants”) on August 3, 2026 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company’s 2025 Inducement Plan. The Inducement Grants were granted as an inducement material to these individuals entering into

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 04 Aug 2026 16:01:00 -0400

NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 12,555 shares of the Company’s common stock to four new employees (the “Inducement Grants”) on August 3, 2026 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company’s 2025 Inducement Plan. The Inducement Grants were granted as an inducement material to these individuals entering into

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 04 Aug 2026 16:01:00 -0400

NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 12,555 shares of the Company’s common stock to four new employees (the “Inducement Grants”) on August 3, 2026 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company’s 2025 Inducement Plan. The Inducement Grants were granted as an inducement material to these individuals entering into

Newleos Names Rohan Palekar as Board Chairman

Tue, 28 Jul 2026 07:00:00 -0400

– Prominent biotech leader and former Chief Executive Officer of 89bio joins Newleos Board of Directors –

BOSTON--(BUSINESS WIRE)-- Newleos Therapeutics, Inc., a clinical-stage biotechnology company developing innovative treatments for neuropsychiatric disorders, today announced the appointment of Rohan Palekar to its Board of Directors. Most recently, Mr. Palekar served as founding Chief Executive Officer at 89bio where he led multiple programs from preclinical studies through Phase 3 development in liver and cardiometabolic diseases. 89bio was acquired by Roche in 2025 for up to $3.5 billion.
This press release features multimedia. View the full

Newleos Names Rohan Palekar as Board Chairman

Tue, 28 Jul 2026 07:00:00 -0400

– Prominent biotech leader and former Chief Executive Officer of 89bio joins Newleos Board of Directors –

BOSTON--(BUSINESS WIRE)-- Newleos Therapeutics, Inc., a clinical-stage biotechnology company developing innovative treatments for neuropsychiatric disorders, today announced the appointment of Rohan Palekar to its Board of Directors. Most recently, Mr. Palekar served as founding Chief Executive Officer at 89bio where he led multiple programs from preclinical studies through Phase 3 development in liver and cardiometabolic diseases. 89bio was acquired by Roche in 2025 for up to $3.5 billion.
This press release features multimedia. View the full